C-NGJ7precision oncology, RAS/MAPK pathway
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Assess safety and tolerability in patients with advanced or metastatic solid tumors with certain KRAS mutations.
Clinical trial administering ERAS-4001 alone or in combination with other treatments.
ClinicalTrials.gov study NCT07021898 published for ERAS-4001 in advanced or metastatic solid tumors.
Assess safety and tolerability in patients with advanced or metastatic solid tumors with certain RAS mutations.
Clinical trial administering ERAS-0015 alone or in combination with other treatments.
ClinicalTrials.gov study NCT06983743 published for ERAS-0015 in advanced or metastatic solid tumors.
Select the optimal naporafenib plus trametinib dose and compare progression-free survival and overall survival against physician's choice therapy in NRAS-mutant melanoma.
SEACRAFT-2 clinical trial of naporafenib administered with trametinib versus physician's choice of dacarbazine, temozolomide, or trametinib monotherapy.
ClinicalTrials.gov study NCT06346067 published for SEACRAFT-2 in NRAS-mutant melanoma.
Evaluate efficacy, safety, tolerability, and pharmacokinetics of naporafenib plus trametinib in patients with RAS Q61X solid tumors.
Clinical trial administering naporafenib with trametinib to patients with RAS Q61X solid tumors.
ClinicalTrials.gov study NCT05907304 published for RAS Q61X solid tumors.
Discover potent and selective KRAS G12D inhibitors for KRAS G12D-mutant cancers including pancreatic ductal adenocarcinoma.
Structure-based drug design and synthesis, with ERK1/2 phosphorylation inhibition, three-dimensional Cell-Titer Glo proliferation assays in AsPC-1 PDAC cells, and in vivo efficacy studies.
2023 ACS Medicinal Chemistry Letters publication described the design and synthesis program leading to ERAS-5024.
ERAS-5024 inhibited ERK1/2 phosphorylation and cell proliferation with single-digit nanomolar potency in AsPC-1 PDAC cells and caused tumor regression in in vivo efficacy studies.
Evaluate safety, tolerability, recommended dose, preliminary efficacy, and pharmacokinetics of ERAS-007 or ERAS-601 combinations in hematologic malignancies.
Clinical trial of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies.
ClinicalTrials.gov study NCT05279859 published for hematologic malignancies.
Evaluate safety, tolerability, recommended dose, antitumor activity, and pharmacokinetics of ERAS-007 combinations in advanced gastrointestinal malignancies.
Clinical trial of escalating doses of ERAS-007 in combination with other cancer therapies.
ClinicalTrials.gov study NCT05039177 published for ERAS-007 in advanced gastrointestinal malignancies.
Evaluate safety, tolerability, recommended dose, antitumor activity, and pharmacokinetics of ERAS-007 or ERAS-601 combinations in advanced non-small cell lung cancer.
Clinical trial of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies.
ClinicalTrials.gov study NCT04959981 published for advanced NSCLC.
Evaluate safety and tolerability of ERAS-007 monotherapy and ERAS-007 in combination with ERAS-601 in advanced or metastatic solid tumors.
Clinical trial of ERAS-007 monotherapy once weekly or twice-daily once-weekly, with combination arms using ERAS-601.
ClinicalTrials.gov study for ERAS-007 as monotherapy or in combination with ERAS-601 in advanced or metastatic solid tumors.
Build a modality-agnostic precision oncology pipeline targeting the RAS/MAPK pathway at multiple points to treat cancers driven by this signaling cascade.
Pipeline strategy focused on shutting down the RAS/MAPK pathway through multiple therapeutic programs.
Company site describes Erasca as a clinical-stage precision oncology company focused on a modality-agnostic RAS/MAPK pathway pipeline.